Advanced search
Add to list

Safety profile and clinical response to MEDI-551, a humanized monoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced B-cell malignancies

(2013) BLOOD. 122(21).
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
Forero-Torres, Andres, Mehdi Hamadani, Michelle A Fanale, et al. “Safety Profile and Clinical Response to MEDI-551, a Humanized Monoclonal anti-CD19, in a Phase 1/2 Study in Adults with Relapsed or Refractory Advanced B-cell Malignancies.” Blood. Vol. 122. 2013. Print.
APA
Forero-Torres, A., Hamadani, M., Fanale, M. A., Bello, C. M., Kipps, T. J., Offner, F., Verhoef, G., et al. (2013). Safety profile and clinical response to MEDI-551, a humanized monoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced B-cell malignancies. BLOOD (Vol. 122). Presented at the 55th Annual meeting of the American Society of Hematology.
Chicago author-date
Forero-Torres, Andres, Mehdi Hamadani, Michelle A Fanale, Celeste M Bello, Thomas J Kipps, Fritz Offner, Gregor Verhoef, et al. 2013. “Safety Profile and Clinical Response to MEDI-551, a Humanized Monoclonal anti-CD19, in a Phase 1/2 Study in Adults with Relapsed or Refractory Advanced B-cell Malignancies.” In Blood. Vol. 122.
Chicago author-date (all authors)
Forero-Torres, Andres, Mehdi Hamadani, Michelle A Fanale, Celeste M Bello, Thomas J Kipps, Fritz Offner, Gregor Verhoef, Massimo Federico, Stephanie A Gregory, Anne Sonet, Sarit Assouline, Jaime Perez de Oteyza, José Francisco Tomas, Antonio Cuneo, Nairouz Elgeioushi, Trishna Goswami, Ramy Ibrahim, Ronald Herbst, and Bruce D Cheson. 2013. “Safety Profile and Clinical Response to MEDI-551, a Humanized Monoclonal anti-CD19, in a Phase 1/2 Study in Adults with Relapsed or Refractory Advanced B-cell Malignancies.” In Blood. Vol. 122.
Vancouver
1.
Forero-Torres A, Hamadani M, Fanale MA, Bello CM, Kipps TJ, Offner F, et al. Safety profile and clinical response to MEDI-551, a humanized monoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced B-cell malignancies. BLOOD. 2013.
IEEE
[1]
A. Forero-Torres et al., “Safety profile and clinical response to MEDI-551, a humanized monoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced B-cell malignancies,” in BLOOD, New Orleans, LA, USA, 2013, vol. 122, no. 21.
@inproceedings{5792523,
  articleno    = {abstract 1810},
  author       = {Forero-Torres, Andres and Hamadani, Mehdi and Fanale, Michelle A and Bello, Celeste M and Kipps, Thomas J and Offner, Fritz and Verhoef, Gregor and Federico, Massimo and Gregory, Stephanie A and Sonet, Anne and Assouline, Sarit and Perez de Oteyza, Jaime and Tomas, José Francisco and Cuneo, Antonio and Elgeioushi, Nairouz and Goswami, Trishna and Ibrahim, Ramy and Herbst, Ronald and Cheson, Bruce D},
  booktitle    = {BLOOD},
  issn         = {0006-4971},
  language     = {eng},
  location     = {New Orleans, LA, USA},
  number       = {21},
  title        = {Safety profile and clinical response to MEDI-551, a humanized monoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced B-cell malignancies},
  volume       = {122},
  year         = {2013},
}

Web of Science
Times cited: